A Phase 1 Study to Assess Safety, Tolerability, and Pharmacokinetics of PUR3100, a Novel Dry Powder Formulation of Dihydroergotamine for Oral Inhalation, in Healthy Adults.

被引：0

作者：

Wasilewski, M. ^{[1
]}

Bodie, S. ^{[1
]}

Gonzalez, Nelson A. ^{[1
]}

Clayton, R. ^{[1
]}

Curran, A. ^{[1
]}

机构：

[1] Pulmatrix Inc, 99 Hayden Ave,Suite 390, Lexington, MA USA

来源：

HEADACHE | 2023年 / 63卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P-05

引用

页码：114 / 115

页数：2

共 50 条

[41] Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study
Ismat, Fraz A.
Usansky, Helen H.
Villa, Raul
Zou, Jun
Teper, Ariel
ADVANCES IN THERAPY, 2022, 39 (11) : 5144 - 5157
[42] Safety, tolerability, and pharmacokinetics (PK) of treprostinil palmitil inhalation powder (TPIP): a phase 1, randomised, double-blind, single- and multiple-dose study
Ismat, F. A.
Usansky, H.
Murthy, S. Dhar
Zou, J.
Teper, A.
EUROPEAN HEART JOURNAL, 2021, 42 : 1954 - 1954
[43] A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants
Gupta, Pranav
Chatterjee, Manash
Kim, Yeonil
Deschamps, Kathleen
Lemoine, Lieselotte
Van Dyck, Kristien
Matthews, Catherine Zhou
Rottey, Sylvie
Stoch, Aubrey
Lai, Eseng
INVESTIGATIONAL NEW DRUGS, 2024, 42 (05) : 492 - 499
[44] A Phase 1 Study to Assess the Pharmacokinetics, Safety, Tolerability and immunogenicity of Fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian Healthy Subjects
Cohen-Barak, Orit
Hu, Xiaojun
Rasamoelisolo, Michele
Faulhaber, Nicola
Yeung, Paul
Yoon, Esther
Gandhi, Mohith
Aycardi, Ernesto
JOURNAL OF HEADACHE AND PAIN, 2017, 18
[45] A Phase 1 Study to Assess the Pharmacokinetics, Safety, Tolerability and immunogenicity of Fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian Healthy Subjects
Cohen-Barak, Orit
Hu, Xiaojun
Rasamoelisolo, Michele
Faulhaber, Nicola
Yeung, Paul
Yoon, Esther
Gandhi, Mohit
Aycardi, Ernesto
JOURNAL OF HEADACHE AND PAIN, 2017, 18
[46] Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
Nakagawa, Hidemi
Nemoto, Osamu
Yamada, Hiroyuki
Nagata, Takeshi
Ninomiya, Noriko
JOURNAL OF DERMATOLOGY, 2018, 45 (06): : 701 - 709
[47] A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB Inhibitor
Dennie, Justin
Vandell, Alexander G.
Inoue, Satoshi
Gajee, Roohi
Pav, Joseph
Zhang, George
Zamora, Cynthia
Masuda, Nobuhisa
Uchiyama, Minoru
Yamada, Makiko
Senaldi, Giorgio
JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (12): : 1557 - 1565
[48] A Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986196, an Oral CNS-penetrant BTK Inhibitor, in Healthy Adults
Goletiani, Nathalie
Goti, Vineet
Boyanapalli, Ramakrishna
Sabet, Ahad
Mirzac, Angela
Syto, Mary
Thomas, Mark
Gleichmann, Marc
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 343 - 343
[49] A FIRST-IN-HUMAN, DOSE-ESCALATION, DRUG-INTERACTION, AND FOOD-EFFECT STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF INCB106385, A SELECTIVE ADENOSINE RECEPTOR ANTAGONIST, IN HEALTHY ADULTS.
Getsy, J.
Barbour, A.
Rockich, K.
Leonetti-Whalen, C.
Yuska, B.
Mcgee, R.
Zhou, G.
Chen, X.
Yeleswaram, S.
Punwani, N.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S22 - S22
[50] A Phase 1 Randomized Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of Dordaviprone and the Effects of Food on the Bioavailability of Dordaviprone in Healthy Adult Subjects
Faison, Shamia L.
Batonga, Joelle
Arumugham, Thangam
Bartkus, Angela
Morrison, Marion
Mullin, Mark J.
Tippin, Tim
Naderer, Odin
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2025,

← 1 2 3 4 5 →